Your browser is no longer supported. Please, upgrade your browser.
BIIB Biogen Inc. monthly Stock Chart
BIIB [NASD]
Biogen Inc.
IndexS&P 500 P/E8.18 EPS (ttm)32.40 Insider Own0.10% Shs Outstand172.80M Perf Week0.95%
Market Cap43.93B Forward P/E8.43 EPS next Y31.44 Insider Trans-1.45% Shs Float161.95M Perf Month-12.39%
Income5.88B PEG- EPS next Q8.08 Inst Own91.40% Short Float2.87% Perf Quarter-12.92%
Sales14.42B P/S3.05 EPS this Y44.80% Inst Trans-4.68% Short Ratio2.50 Perf Half Y-9.90%
Book/sh72.61 P/B3.65 EPS next Y-4.75% ROA22.00% Target Price308.64 Perf Year11.27%
Cash/sh23.30 P/C11.38 EPS next 5Y-2.68% ROE44.50% 52W Range215.77 - 374.99 Perf YTD-10.65%
Dividend- P/FCF6.63 EPS past 5Y20.50% ROI30.50% 52W High-29.30% Beta0.54
Dividend %- Quick Ratio1.50 Sales past 5Y8.20% Gross Margin87.50% 52W Low22.87% ATR8.19
Employees7400 Current Ratio1.70 Sales Q/Q1.30% Oper. Margin51.00% RSI (14)39.15 Volatility2.31% 2.82%
OptionableYes Debt/Eq0.48 EPS Q/Q13.00% Profit Margin40.80% Rel Volume0.51 Prev Close264.77
ShortableYes LT Debt/Eq0.36 EarningsApr 22 BMO Payout0.00% Avg Volume1.86M Price265.12
Recom2.80 SMA20-4.32% SMA50-9.95% SMA200-8.78% Volume942,858 Change0.13%
Jun-22-20Reiterated RBC Capital Mkts Sector Perform $303 → $273
Jun-22-20Downgrade Barclays Overweight → Equal Weight $370 → $280
Jun-09-20Downgrade Bernstein Outperform → Mkt Perform $360 → $297
Apr-23-20Downgrade Raymond James Mkt Perform → Underperform
Apr-23-20Downgrade Citigroup Neutral → Sell $365 → $240
Mar-31-20Initiated Wolfe Research Peer Perform
Feb-27-20Initiated Barclays Overweight $389
Jan-27-20Upgrade Canaccord Genuity Hold → Buy $360
Dec-13-19Upgrade Credit Suisse Underperform → Neutral $260 → $300
Dec-02-19Downgrade Robert W. Baird Neutral → Underperform
Nov-12-19Initiated SunTrust Buy $337
Nov-01-19Downgrade Standpoint Research Buy → Hold
Oct-30-19Upgrade Bernstein Mkt Perform → Outperform
Oct-23-19Upgrade SVB Leerink Mkt Perform → Outperform $256 → $350
Oct-23-19Upgrade Guggenheim Neutral → Buy $256 → $365
Oct-23-19Reiterated H.C. Wainwright Buy $300 → $335
Oct-23-19Reiterated BofA/Merrill Underperform $200 → $235
Oct-17-19Resumed BofA/Merrill Underperform $200
Jun-28-19Downgrade Piper Jaffray Overweight → Neutral $280 → $250
Jun-05-19Upgrade Standpoint Research Hold → Buy
Jul-02-20 05:30PM  
04:51PM  
09:00AM  
Jul-01-20 07:37AM  
Jun-30-20 04:26PM  
11:18AM  
Jun-29-20 10:49AM  
Jun-25-20 01:44PM  
Jun-22-20 04:56PM  
12:04PM  
10:29AM  
Jun-20-20 09:48AM  
Jun-19-20 06:43PM  
06:04PM  
11:00AM  
10:22AM  
09:34AM  
Jun-18-20 09:40PM  
06:52PM  
05:53PM  
04:46PM  
04:21PM  
02:19PM  
01:31PM  
12:24PM  
11:55AM  
11:08AM  
11:02AM  
10:55AM  
Jun-17-20 11:06AM  
09:53AM  
Jun-16-20 09:50AM  
08:45AM  
Jun-15-20 09:24AM  
Jun-11-20 02:45PM  
09:19AM  
09:00AM  
Jun-10-20 03:30PM  
12:04PM  
09:50AM  
08:56AM  
07:30AM  
Jun-09-20 12:30PM  
11:35AM  
09:45AM  
08:24AM  
06:46AM  
Jun-05-20 10:42AM  
Jun-04-20 09:11AM  
08:45AM  
07:30AM  
Jun-03-20 09:52AM  
09:42AM  
08:26AM  
Jun-02-20 10:18AM  
Jun-01-20 09:52AM  
May-29-20 08:47AM  
08:00AM  
May-28-20 07:30AM  
May-26-20 12:55PM  
06:44AM  
05:37AM  
May-23-20 07:36AM  
May-22-20 06:04PM  
09:05AM  
06:07AM  
May-20-20 09:23AM  
08:58AM  
May-19-20 09:48AM  
07:30AM  
May-18-20 02:47PM  
07:30AM  
May-15-20 10:18AM  
May-14-20 10:00AM  
09:34AM  
09:28AM  
May-13-20 01:16PM  
10:09AM  
10:05AM  
May-12-20 04:01PM  
10:03AM  
10:00AM  
May-11-20 05:40PM  
11:58AM  
10:26AM  
10:07AM  
09:52AM  
May-08-20 10:33AM  
08:59AM  
08:51AM  
08:50AM  
08:50AM  
07:57AM  
May-07-20 03:28PM  
11:03AM  
10:40AM  
10:33AM  
09:14AM  
09:09AM  
May-06-20 11:48AM  
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it is involved in developing Opicinumab, BIIB061, and BIIB091 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB110, and BIIB100 to treat neuromuscular disorders; BIIB054 and BIIB094 for treating movement disorders; BIIB111 and BIIB112 for ophthalmology; Dapirolizumab pegol and BIIB059 to treat immunology and others; BIIB104 for neurocognitive disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB074 and BIIB095 for pain; and SB11 biosimilar, which are under various stages of development. The company offers products through its sales force and marketing groups. Biogen Inc. has collaboration agreements with Genentech, Inc.; Ionis Pharmaceuticals, Inc.; Eisai Co., Ltd.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Acorda Therapeutics, Inc.; AbbVie Inc.; Skyhawk Therapeutics, Inc.; Neurimmune SubOne AG; and Sangamo Therapeutics Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SHERWIN STEPHEN ADirectorMar 11Option Exercise58.4612,278717,77216,517Mar 12 06:56 PM
SHERWIN STEPHEN ADirectorMar 11Sale295.222,434718,57414,353Mar 12 06:56 PM
Vounatsos MichelChief Executive OfficerFeb 15Option Exercise0.004,847033,775Feb 19 06:20 PM
Sandrock AlfredEVP, Research & DevelopmentFeb 15Option Exercise0.001,213015,019Feb 19 06:17 PM
Galdes AlphonseEVP Pharmaceutical Oper & TechFeb 15Option Exercise0.0044102,672Feb 19 06:13 PM
ALEXANDER SUSAN HEVP Chief Legal Off & Corp SecFeb 15Option Exercise0.001,553037,261Feb 19 06:09 PM
Kramer RobinVP, Chief Accounting OfficerFeb 12Option Exercise0.001320282Feb 14 06:37 PM
Karp DanielEVP, Corporate DevelopmentFeb 12Option Exercise0.0096001,224Feb 14 06:36 PM
Guindo ChirfiEVP Glob. Prod Strat and CommFeb 12Option Exercise0.001,68004,375Feb 14 06:34 PM
Gregory GingerEVP, Human ResourcesFeb 12Option Exercise0.003,54705,021Feb 14 06:32 PM
Galdes AlphonseEVP Pharmaceutical Oper & TechFeb 12Option Exercise0.001,15402,337Feb 14 06:30 PM
CAPELLO JEFFREY DEVP & Chief Financial OfficerFeb 12Option Exercise0.001,91903,732Feb 14 06:27 PM
ALEXANDER SUSAN HEVP Chief Legal Off & Corp SecFeb 12Option Exercise0.005,967036,389Feb 14 06:25 PM
Vounatsos MichelChief Executive OfficerFeb 12Option Exercise0.0011,994031,483Feb 14 06:19 PM
Sandrock AlfredEVP, Research & DevelopmentFeb 12Option Exercise0.005,216014,509Feb 14 06:16 PM
CAPELLO JEFFREY DEVP & Chief Financial OfficerJan 02Option Exercise0.001,30202,219Jan 06 04:14 PM
Kramer RobinVP, Chief Accounting OfficerDec 03Option Exercise0.00840175Dec 05 04:24 PM
Posner Brian SDirectorDec 02Sale292.351,055308,4296,995Dec 03 05:58 PM
Guindo ChirfiEVP Glob. Prod Strat and CommDec 01Option Exercise0.0054302,855Dec 03 05:59 PM
Gregory GingerEVP, Human ResourcesAug 01Option Exercise0.0017902,295Aug 05 04:20 PM